Catabasis Uses New Financing To Take Two Programs Forward Simultaneously
This article was originally published in The Pink Sheet Daily
The biotech now has the funding to move a second program into the clinic; a program it hopes to carry to approval on its own.
You may also be interested in...
The New Jersey biotech submitted the NDA for its omega-3 fatty acid drug with FDA.
A second set of clinical trial results expands the potential market for AMR101 tenfold, triggering increased investor and partnership interest.
Nutritional industry stakeholders say the jury is still out on how omega-3 pharmaceuticals will affect the supplement space long-term, but supplement marketers should do everything they can to step up their game.